Cargando…
Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several promising PSMA inhibitors from a variety of molecular...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tabriz University of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676551/ https://www.ncbi.nlm.nih.gov/pubmed/38022814 http://dx.doi.org/10.34172/apb.2023.079 |
_version_ | 1785141306980302848 |
---|---|
author | Ritawidya, Rien Wongso, Hendris Effendi, Nurmaya Pujiyanto, Anung Lestari, Wening Setiawan, Herlan Humani, Titis Sekar |
author_facet | Ritawidya, Rien Wongso, Hendris Effendi, Nurmaya Pujiyanto, Anung Lestari, Wening Setiawan, Herlan Humani, Titis Sekar |
author_sort | Ritawidya, Rien |
collection | PubMed |
description | Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several promising PSMA inhibitors from a variety of molecular scaffolds (e.g., phosphorous-, thiol-, and urea-based molecules) have been developed. In addition, PSMA inhibitors bearing macrocyclic chelators have attracted interest due to their favorable pharmacokinetic properties. Recently, conjugating a small PSMA molecule inhibitor-bearing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator, as exemplified by [(177)Lu]Lu-PSMA-617 could serve as a molecular imaging probe and targeted radioligand therapy (TRT) of metastatic castration resistant prostate cancer (mCRPC). Hence, studies related to mCRPC have drawn global attention. In this review, the recent development of PSMA ligand-617-labeled with (177)Lu for the management of mCRPC is presented. Its molecular mechanism of action, safety, efficacy, and future direction are also described. |
format | Online Article Text |
id | pubmed-10676551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Tabriz University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-106765512023-04-29 Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer Ritawidya, Rien Wongso, Hendris Effendi, Nurmaya Pujiyanto, Anung Lestari, Wening Setiawan, Herlan Humani, Titis Sekar Adv Pharm Bull Review Article Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several promising PSMA inhibitors from a variety of molecular scaffolds (e.g., phosphorous-, thiol-, and urea-based molecules) have been developed. In addition, PSMA inhibitors bearing macrocyclic chelators have attracted interest due to their favorable pharmacokinetic properties. Recently, conjugating a small PSMA molecule inhibitor-bearing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator, as exemplified by [(177)Lu]Lu-PSMA-617 could serve as a molecular imaging probe and targeted radioligand therapy (TRT) of metastatic castration resistant prostate cancer (mCRPC). Hence, studies related to mCRPC have drawn global attention. In this review, the recent development of PSMA ligand-617-labeled with (177)Lu for the management of mCRPC is presented. Its molecular mechanism of action, safety, efficacy, and future direction are also described. Tabriz University of Medical Sciences 2023-11 2023-04-29 /pmc/articles/PMC10676551/ /pubmed/38022814 http://dx.doi.org/10.34172/apb.2023.079 Text en ©2023 The Authors. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. |
spellingShingle | Review Article Ritawidya, Rien Wongso, Hendris Effendi, Nurmaya Pujiyanto, Anung Lestari, Wening Setiawan, Herlan Humani, Titis Sekar Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer |
title | Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer |
title_full | Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer |
title_fullStr | Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer |
title_full_unstemmed | Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer |
title_short | Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer |
title_sort | lutetium-177-labeled prostate-specific membrane antigen-617 for molecular imaging and targeted radioligand therapy of prostate cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676551/ https://www.ncbi.nlm.nih.gov/pubmed/38022814 http://dx.doi.org/10.34172/apb.2023.079 |
work_keys_str_mv | AT ritawidyarien lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer AT wongsohendris lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer AT effendinurmaya lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer AT pujiyantoanung lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer AT lestariwening lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer AT setiawanherlan lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer AT humanititissekar lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer |